 
Neoadjuvant Imiquimod for Oral Cancer  
 
Protocol Number: 103625  
National Clinical Trial (NCT) Identified Number:  04883645  
Principal Investigator:  [INVESTIGATOR_670294], DDS  
Sponsor: Investigator -sponsored   
Funded by : [CONTACT_4289]/NCI  
Version Number:  9 .3 
Date: 15 NOV 2023 
 
 
Summary of Changes  from Previous Version:  
Affected 
Section(s)  Summary of Revisions Made  Rationale  
All Organization change  [CONTACT_670350] relocated from Columbia 
University to MUSC.  
3, 9 Addition of tumor cell quantification using 
immunofluorescence in the primary endpoint 
assessment  
Additional statistical analyses  as required  Expansion of laboratory techniques to evaluate primary endpoint  

  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  ii Table of Contents  
Table of Contents  .................................................................................................................................................... ii 
STATEMENT OF COMPLIANCE  ............................................................................................................................. 1 
1 PROTOCOL SUMMARY .................................................................................................................................... 2 
1.1 Synopsis  ........................................................................................................................................................... 2 
1.2 Schema  ............................................................................................................................................................ 3 
1.3 SCHEDULE OF ACTIVITIES (SoA)  ............................................................................................................. 5 
2 INTRODUCTION  ................................................................................................................................................. 6 
2.1 Study Rationale  ............................................................................................................................................... 6 
2.2 Background  ...................................................................................................................................................... 7 
2.3 Risk/Benefit Assessment  ............................................................................................................................... 7 
2.3.1  Known Potential Risks  ............................................................................................................................ 7 
2.3.2  Known Potential Benefits  ....................................................................................................................... 9 
2.3.3  Assessment of Potential Risks and Benefits  ....................................................................................... 9 
3 OBJECTIVES AND ENDPOINTS  ..................................................................................................................... 9 
4 STUDY DESIGN  ............................................................................................................................................... 10 
4.1 Overall Design  ............................................................................................................................................... 10 
4.2 Scientific Rationale for Study Design  ......................................................................................................... 11 
4.3 Justification for Dose  .................................................................................................................................... 11 
4.4 End of Study Definition  .................................................................................................................................  11 
5 STUDY POPULATION  ..................................................................................................................................... 11 
5.1 Inclusion Criteria  ........................................................................................................................................... 11 
5.2 Exclusion Criteria  .......................................................................................................................................... 11 
5.3 Lifestyle Considerations  ............................................................................................................................... 12 
5.4 Screen Failures  ............................................................................................................................................. 12 
5.5 Strategies for Recruitment and Retention  .................................................................................................  12 
6 STUDY INTERVENTION  .................................................................................................................................  13 
6.1 Study Intervention(s) Administration  .......................................................................................................... 13 
6.1.1  Study Intervention Description  ............................................................................................................ 13 
6.1.2  Dosing and Administration  ................................................................................................................... 14 
6.2 Preparation/Handling/Storage/Accountability  ........................................................................................... [ADDRESS_904925] Storage and Stability  .............................................................................................................. 15 
6.2.4  Preparation  15 
6.3 Measures to Minimize Bias: Randomization and Blinding ...................................................................... 15 
6.4 Study Intervention Compliance ................................................................................................................... 15 
6.5 Concomitant Therapy  ................................................................................................................................... 15 
6.5.1  Rescue Medicine  15 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  .................................................................................................................... 16 
7.1 Discontinuation of Study Intervention  ........................................................................................................ 16 
7.2 Participant Discontinuation/Withdrawal from the Study  .......................................................................... [ADDRESS_904926] to Follow -Up .......................................................................................................................................... 17 
8 STUDY ASSESSMENTS AND PROCEDURES  .......................................................................................... 17 
8.1 Efficacy Assessments .................................................................................................................................. 17 
8.2 Safety and Other Assessments  .................................................................................................................. 18 
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  iii 8.3 Adverse Events and Serious Adverse Events  .......................................................................................... 18 
8.3.1  Definition of Adverse Events (AE)  ...................................................................................................... 18 
8.3.2  Definition of Serious Adverse Events (SAE)  ..................................................................................... [ADDRESS_904927]  .................................................................................................................... 21 
8.3.9  Reporting of Pregnancy  ........................................................................................................................ 21 
8.4 Unanticipated Problems  ............................................................................................................................... 21 
8.4.1  Definition of Unanticipated Problems (UP)  ........................................................................................ 21 
8.4.2  Unanticipated Problem Reporting  ....................................................................................................... 22 
8.4.3  Reporting Unanticipated Problems to Participants  ........................................................................... 22 
9 STATISTICAL CONSIDERATIONS  ............................................................................................................... 22 
9.1 Statistical Hypotheses  .................................................................................................................................. 23 
9.2 Sample Size Determination  ......................................................................................................................... 23 
9.3 Populations for Analyses  ............................................................................................................................. 23 
9.4 Statistical Analyses  ....................................................................................................................................... 23 
9.4.1  General Approach  23 
9.4.2  Analysis of the Primary Efficacy Endpoint  ......................................................................................... 24 
9.4.3  Analysis of the Secondary Endpoint / safety endpoint  .................................................................... [ADDRESS_904928] Policy  ................................................................................................................. 31 
10.2  Additional Considerations  ............................................................................................................................ 31 
10.3  Abbreviations  ................................................................................................................................................. 32 
10.4  Protocol Amendment History ....................................................................................................................... 34 
11 REFERENCES  .................................................................................................................................................. 36 
Appendix A: ECOG Performance Status Criteria.  ............................................................................................ 40 
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  iv Appendix B: Daily Diary  ....................................................................................................................................... 41 
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   1 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonisation Good 
Clinical Practice ( ICH GCP) and the following :  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12)  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are 
responsible  for the conduct, management, or  oversight of NIH -funded clinical trials  have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by [CONTACT_3484].  In addition, all changes to the consent form will be IRB -approved; a 
determination will be made regarding whether a new consent needs to be obtained from 
participants  who provided consent , using a previously approved consent form . 
     
 
         
 
         
 
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   2 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
 
Title:   
Exploratory clinical trial of topi[INVESTIGATOR_241129] 5% cream as window -of-
opportunity monotherapy for early -stage oral cancer  
 
Study Des cription :  
Our aim is to conduct a n exploratory clinical trial to assess the efficacy of 
neoadjuvant imiquimod immunomodulatory topi[INVESTIGATOR_670295] -
stage oral cancer patients .  
 
Objectives:  
 Primary Objective:  To assess the preliminary efficacy of topi[INVESTIGATOR_670296] -stage oral squamous cell 
carcinoma as determined by a minimum of 50% reduction in tumor assessed 
first by [CONTACT_670323] . 
Secondary Objective: To assess local and systemic safety and 
tolerability by [CONTACT_3989] v5 criteria.  
Exploratory Objective: To explore the effect of imiquimod on the tumor immune microenvironment (immune profile) by [CONTACT_670324].  
Endpoint s: Primary Endpoint : The primary endpoint is the overall clinical and 
histological  response rate as defined as the precent reduction in tumor 
size obtained by [CONTACT_670325] , and the percent  change in tumor cell count  
assessed first by [CONTACT_670326]  , confirmed at 4 weeks of 
the start of study therapy . 
Secondary Endpoints : The secondary endpoint is defined as safety and 
toxicity assessed using CTCAE v5.0 criteria . 
Study Population:  A total of 15 subjects will be accrued. We will accrue oral squamous cell 
carcinoma ( OSCC ) patient  ≥[ADDRESS_904929] an 
ECOG performance status of ≤2 at MU SC, South Carolina.  
 
Phase:   
0 (Exploratory)  
 
Description of Sites /Facilities  Enrolling  
Participants :  
This is an open -label, single -center clinical trial  that will be conducted in 
Hollings Cancer Center at MUSC .   
  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   3 Description of Study  
Intervention: Off-label use of imiquimod 5% topi[INVESTIGATOR_68549]:  The patient will be 
instructed to apply imiquimod cream, [ADDRESS_904930] 2 cm beyond the outlined tumor 
margins to cover potentially cancerized field.  
 
Study Duration:   
2-years  
 
Participa nt Duration:   
1 month  
 
1.2 SCHEMA  
 
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   4  
 
  Screening Visit Days -14 to -1
•Phone call (PI): Reach out to patients with histologic confirmation of OSCC, ensure patient is not 
immunocompromised or on immunosuppressive medication, otherwise in good health or have conditions well 
managed by [CONTACT_12617]; if eligible, ask the patient to come in for a screening visit, email informed consent
•Screening visit : Review and obtain informed consent, complete demographic/medical history form, prior/active 
medication form; oral examination (no other tumor should be present), take cinical photo, measure tumor size; 
provide instruction for imiquimod application & daily diary form. *This is to be completed prior to initiation of 
the study drug on Day 1.
•(SOC) Head & Neck initial consultation: Schedule for the surgery ~4 weeks from Day 1
•Blood draw (CBC): SOC as a part of H&N consult. Obtain and keep record of baseline CBC for comparison with 
that at the endpoint (immiediately prior to surgery); if the patient is a women of child bearing potential, 
pregnancy test is to be performed to meet the eligibility criteria (cost covered by [CONTACT_1758])
•Request research pharmacy to dispense imiquimod 5% cream (28 packets)
Baseline (Day 1) Televisit Day 1
•Ask the patient to start medication and contact [CONTACT_976] [INVESTIGATOR_670297] 14 (+/ -5 days)
•Oral examination, tumor measurements, and take photo
•Check adverse eventsMidpoint (Day 14) Cinic Visit
Day 29 (+/ -5 days)
•Oral examination, tumor measurements, and take photo
•Adverse events form
•Concomitant medication form
•Collect Daily Diary form
•Compliance form
•Collect remaining medication and send to the research pharmacy
One-Month Follow -up phone call Day 60 (+/ -7 days)
•Check for ongoing adverse events
•Concomitant medicationEndpoint (Day 29) Televisit
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   5 1.3 SCHEDULE OF ACTIVITIES (SOA)  
 
*Days -14 to -1: Excludes weekends (Saturday, Sunday) and holidays  
*+/-5 days for Day 14  and Day 29: Excludes weekends (Saturday, Sunday) and holidays  
 
 
 
 
  
 
 
 
  
 
 
 
  Procedure  Days  -14 to -1* Day 1  
(Televisit)   Day 14 
(+/-5)* Day 2 9 
(+/-5)* Day 30  
(+/-14) Day 60  
(+/-7)   
Screening Visit  
Histology confirmation of 
OSCC in the biopsy 
specimen (SOC)  
  
x      
Inclusion/Exclusion Criteria  x      
Informed Consent  x      
Demographics/Medical 
History  x      
Prior/Active Medication 
Review  x      
Blood draw  (CBC ); Serum 
pregnancy test if women of 
childbearing potential)  X (SOC for CBC)     x (SOC)   
H&N Surgical Consult  x (SOC)       
Baseline Symptoms Form  x      
Physical Symptoms Form  x      
Oral Examination/Tumor 
measurements/Photography  x  x x   
 
Treatment Administration   Topi[INVESTIGATOR_241129] 5% cream application  
(Days 1- 28) 
(Apply one single- use packet daily before 
bed)   
Adverse Events Form    x x  x 
Daily Diary Form     x   
Concomitant Medication 
Form     x  x 
Compliance Form     x   
 
Surgical Resection  
      
x (SOC)   
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904931] efficacious treatment regimen for patients with early -stage 
(TNM Stages I/II) oral squamous cell carcinoma (OSCC). Since 80% of oral cancer patients are in early 
stage at the time of diagnosis2, there exists a window of opportunity in which accurate prognostication 
and subsequent decisions for appropriate treatment will dramatically improve the 5 -year survival of 
patients with this deadly disease.  
For early -stage oral cancer patients, the five -year survival rate is estimated to be 60%7. We are currently 
developi[INVESTIGATOR_007] a microRNA -based prognostic model to distinguish the 40% who will die of the disease from 
the 60% who will most likely survive15. However, treatment modalities for those at a high risk for cancer-
specific mortality remains unexplored. It is imperative to discover effective therapy for the early -stage 
oral cancer patients who have a poor prognosis and are at a high cancer- specific m ortality risk following 
standard surgical treatment.  
To address these critical gaps, we propose to assess the efficacy of a topi[INVESTIGATOR_160772] 5% cream in an 
exploratory clinical trial as a ‘window -of-opportunity’ monotherapy, administered between the biopsy 
confirmation of OSCC and the initial tumor surgery.  Imiquimod is an FDA -approved Toll -like receptor 
agonist (TLR)16-25. We have previously reported that intra -oral application of topi[INVESTIGATOR_670298] a recurrence -free [ADDRESS_904932] -
treatment  tumor  specimen  collected from  patients  treated  on  this  study  will  be  used  for  quantitative immunofluorescence  analysis  to  assess  the immunomodulatory activity of imiquimod in 
human tumor samples. We hypothesize that TLR -7 stimulation  will reduce the size of the tumor  in 
patients  with  early -stage oral squamous cell carcinoma. We anticipate that activation of CD4+ T -cell and 
macrophage will correlate with response to therapy.  
 
  
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   7 2.2 BACKGROUND   
 
T
opi[INVESTIGATOR_160772] 5% cream is a FDA- approved TLR (Toll -like receptor) agonist. Imiquimod immune -
modulatory therapy has aroused considerable cancer clinical research interest and showed promising 
results in clinical trials. Imiquimod induces apoptosis and necrosis of tumor cells. Imiquim od-i
nduced 
necrosis of OSCC cells leads to release of high mobility group box 1 (HMGB1) protein, which in turn acts 
as a chemokine and induces a pro -inflammatory response16-24. Given that a wide variety of genetic and 
epi[INVESTIGATOR_670299], therapeutic agents with the ability to induce 
tumor necrosis are advantageous16. Imiquimod also initiates tumor cell apoptosis by [CONTACT_670327] - 
and anti -apoptotic Bcl factors toward the pro -apoptotic Bax protein, and by [CONTACT_670328] c into the cytosol, activating caspase -9 and caspase -321-23. Indeed, a study 
showed that imiquimod increased both apoptosis and necrosis of OSCC cells (32.03% and 15.23%, respectively)
24. 
 
M
oreover, imiquimod is an immune response modifier, activating macrophages and other cells via TLR7. 
Imiquimod provokes Th1 cell -mediated immune response by [CONTACT_670329]- α (IFN -α), tumor necrosis factor -α (TNF -α) and interleukin -12 (IL -12)23-25. 
Currently, imiquimod as a 5% cream is being used to treat several skin cancers, including malignant 
melanoma, basal cell carcinoma (BCC) and SCC26-28. With respect to SCC treatment, it has been 
demonstrated t hat imiquimod stimulates tumor destruction by [CONTACT_670330] T cells 
from blood and by [CONTACT_670331] -inflammatory signals within the tumor29. Other evidence shows 
that topi[INVESTIGATOR_670300] -induced SCC through activation 
of Th17/Th1 cells and cytotoxic T lymphocytes30. While surgical excision is the first line treatment, 
imiquimod has been shown to be an efficacious, non -invasive topi[INVESTIGATOR_670301], especially 
when utilized in the neoa djuvant setting prior to initial surgery.  Taken together, imiquimod is a 
promising agent in the treatment of squamous cell carcinoma involving oral mucosa.  
 
2.3 RISK/BENEFIT ASSESSMENT   
 
2.3.1  KNOWN  POTENTIAL RISKS  
 
Application site reactions: 
• Redness, itching, burning, or bleeding of the treated area (33%)  
• flaking, scaling, dryness, or thickening of the skin (33%)  
• swelling, stinging, or pain in the treated area (33%)  
• blisters, scabs, or bumps on the skin (33%)  
• inflammation or swelling of the tissue lining the sinuses (7%)  
• headache (11%)  
• diarrhea (3%)  
• red and itchy skin reaction (2%)  
• back pain (1%)  
• tiredness (1%)  
• irregular and rapid heat rate (1%)  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   8 • virus infection (1%)  
• dizziness (1%)  
• vomiting (1%)  
• infection of any part of urinary system (1%)  
• fever (1%)  
• tremor caused by a chill (1%)  
Systemic side effects :  
• Flu-like symptoms such as nausea, fever, chills, tiredness, and muscle weakness or pain 
(15%)  
Women of child- bearing potential: Pregnancy Category C: There are no adequate and well -controlled 
studies in pregnant women. Imiquimod cream should be used during pregnancy only if the potential 
benefit justifies the potential risk to the fetus.  
Breast -f eeding: Women using imiquimod should not breast -feed as it is not known whether topi[INVESTIGATOR_670302].  
Overdosage : P ersistent topi[INVESTIGATOR_670303]. The most clinically serious adverse event reported following multiple oral imiquimod doses of >200 mg (equivalent to imiquimod content of 
>16 packets) was hypotension, which resolved following oral or intravenous fluid administration.  
Alternative Procedures : P
 atients  may  continue  imiquimod  for  Grade  1  or  tolerable  Grade  2  toxicity  
without  a  dose reduction (graded according to NCI CTCAE v5.0).  For  intolerable  Grade  2,  Grade  [ADDRESS_904933]  be  withheld until the toxicity has resolve to Grade 1 or tolerable 
Grade 2. At the discretion of the treating clinician,  imiquimod  may  then  be  resumed  as  per  following  guidelines  (Table  1) .  If an adverse event is not covered in the table, dos es may be reduced or held at 
the discretion of the investigator for the subject’s safety (eg, once every other day). The tables are intended to serve as guidance and cases in which  the  management  is  unclear  should  be  discussed  with  the  principal  investigator  [INVESTIGATOR_670304].  
Subjects with adverse events that are manageable with supportive therapy may not require dose 
reductions (e.g., local site irritation may be treated with non -medicating moisturizing gel rather than by 
[CONTACT_29874]).  
Subjects will be withdrawn from the study treatment if they fail to recover to Grade 0, Grade 1 or 
tolerable grade 2 (or within 1 grade of starting values for pre -existing laboratory abnormalities) from  a  
treatment- related  adverse  event  within  [ADDRESS_904934] should remain on t he study because of evidence that the patient is/may continue deriving 
benefit from continuing study treatment.  
Doses should not be increased during the 4 weeks of therapy.  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   9 Table 1. Dose Modifications  
 
   
 
 
 
2.3.2  KNOWN POTENTIAL BENEFITS  
 
Topi[INVESTIGATOR_670305] 5% cream may reduce the size of the tumor, so that less tissue will have to be removed at the time of surgery.  
 
2.3.[ADDRESS_904935] line treatment, imiquimod has been shown to be an efficacious, non -
invasive topi[INVESTIGATOR_670301], especially when utilized in the neoadjuvant setting prior to initial 
surgery
31-34. A topi[INVESTIGATOR_670306], hence, it is well tolerated with negligible systemic adverse events28. 
 
3 OBJECTIVES AND ENDPOINTS  
 
Type  Name  [CONTACT_670349], confirmed by 
[CONTACT_670332]   4-weeks  compared 
to baseline  Change in tumor size measured at the endpoint 
compared to that of the baseline, histologically 
assessed by [CONTACT_670333] , which is 
quantitatively confirmed by [CONTACT_670334],  
compared to that of the biopsy  
Secondary  Safety and tolerability of 
topi[INVESTIGATOR_160772] 5% 
cream  Continuously during 
the study and for 4-weeks  after the last 
dose of treatment  Safety and toxicity will be assessed using CTCAE 
v5.[ADDRESS_904936] of imiquimod using 
quantitative multiplex immunofluorescence  
 
  
 
  Dose Level  Dose  
0 Apply once every day  
-1 Apply once in two days  
-2 Apply once in three days  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   10  
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 
We hypothesize that Imiquimod 5% topi[INVESTIGATOR_670307] 28 days  will 
significantly decrease the clinical tumor size with confirmation by [CONTACT_27183]. Minimal local and 
systemic adverse events are anticipated.  
 This is a single -arm, phase 0 exploratory study evaluating the efficacy of imiquimod 5% cr eam in 
early -stage oral cancer patients.  
 
Study Intervention : All subjects will apply imiquimod 5% cream on the oral tumor and adjacent area, 
once a day before  bedtime, for 28-days . 
 
Schedule of Evaluations : Formal tumor measurements (length of longest dimension i n cm) with 
photography will be performed and the baseline blood test result recorded. Safety assessment (documentati on of side effects experienced by [CONTACT_2299]) and tumor measurement will be 
performed at the midpoint visit. Th e safety assessment, including routine blood work and intra -oral 
clinical examinations, will be performed and the tumor size measured at the endpoint  visit. 
 
Response to treatment will be determined by [CONTACT_670335] : 
Decrease in tumor size measured at the endpoint compared to that of the baseline, histologically 
assessed by [CONTACT_670336], which is quantitatively confirmed by [CONTACT_670337]. Toxicity eval uation will utilize CTCAE 
v5.0 criteria.  
 
Duration of Treatment: Subjects will continue treatment for a total of 28 -days , unti l confirmed 
disease progression  (defined as doubling of tumor size compared to baseline) or intolerable toxicity 
or side effects. Subjects will be  withdrawn from the study and proceed with scheduled surgical 
excision.  
 
Duration of Follow -Up: Toxicity will be graded using the NCI CTCAE v5.[ADDRESS_904937] reco vered to baseline or are deemed  irreversible by [CONTACT_093]. Subjects 
who are removed from study for reasons other t han progression of disease will be followed every 3 
months to evaluate disease status and survival analysis while the study remains open.  
 
The current study is limited to assessing the endpoint response at the week 4 mark. However, lack of rapid tumor regression might not mean that the treatment was ineffective, and rapid early regression may be associated with no long- term benefits. Moreover , immune therapi[INVESTIGATOR_670308] 4 weeks to work; therefore, clinical response may be underestimated with this duration. We will continue to follow the current cohort via periodic review of the electronic medical record beyond the R21 project term , and collect the recurrence and survival data to gain insight into the 
long- term effect of imiquimod.  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   11  
  
4.2 SCIENTIFIC R ATIONALE FOR S TUDY DESIGN  
 This is an exploratory single -arm study.
 
 
4.3 JUSTIFICATION FOR DO SE 
 The dosing schedule and treatment duration are not standardized
49. The recommended schedule in the 
US and Europe is 5 times a week for 6 weeks with a success rate of 73 –77%32,50 – this is a total of 30 days 
of treatment, which is equivalent to 7 times a week for 4 weeks (a total of 28 days). Topi[INVESTIGATOR_670309] [ADDRESS_904938] meet all of the following criteria:  
 
1. Provision of signed and dated informed consent form  
 
2. Stated willingness to comply with all study procedures and availab ility for the duration of the 
study  
 
3. Biopsy confirmed primary oral squamous cell carcinoma (OSCC)  
 
4. Clinical (TNM) stage I or II  
 
5. Age >= 18 years  
 
6. ECOG =< 2 . 
 
 
5.2 EXCLUSION CRITERIA  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   12  
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
1.  Patients currently on  system ic or intraoral immunosuppressive therapy  
2.  Treatment with any other investigational agents  for OSCC  
3.  HIV positive patients on combination antiretroviral therapy  
4.  Pregnant women are excluded from this study because imiquimod may have adverse effect on 
the fetus (FDA pregnancy risk category C). Because there is an unknown but potential risk for 
adverse events in nursing infants secondary to treatment of the mother  with imiquimod, 
breastfeeding should be discontinued if the mother is receiving study treatment  
5.  Male patients unwilling or unable to comply wit h pregnancy prevention measures  
6.  Subjects not receiving initial surgical treatment at MUSC . 
 
5.3 LIFESTYLE CONSIDERATIONS  
 During this study , participants are asked to:  
• Abstain from eating or drinking for at least 30 minutes after application of topi[INVESTIGATOR_670310].  
 
5.4 SCREEN FAILURES  
 Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently entered in the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants , to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, and eligibility criteria.  
 Individuals  who do not meet the criteria for participation in this trial (screen failure) , tests with results 
that fail eligibility requirements may be repeated during the screening phase if the investigator believes the results to be in error. Additionally, a subject who fails screening may repeat the screening process 1 time if the investigator believes there has been a c hange in eligibility status (eg, after recovery from an 
infection).  
 
5.[ADDRESS_904939] patient will be enrolled 
approximately 3-5 months after the study initiation at MUSC .  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   13 The MUSC  Oral Biopsy Laboratory  receives ~ 7000 specimens from the tristate area annually. 
Approximately 150-200 cases are of OSCC (oral squamous cell carcinoma). As these are biopsy 
specimens from the private dental practices, most of these OSCC are of early clinical stages. Once the 
histologic diagnosis of OSCC is rendered, the submitting clinician will be contac ted by [CONTACT_978], who is the 
case pathologist, for permission to directly speak with the patient. The patient will be informed of the 
clinical trial and referred to the MUSC  Head and Neck Surgery for the initial consultation, at which time 
the medical history is reviewed and treatment option (surgery alone vs surgery with elective neck 
dissection) is discussed. If eligible, the patient will be approached to obtain consent. The surgeon will be 
informed of the patient’s involvement in the clinical trial and the surgery will be scheduled for [ADDRESS_904940] number provided on the consent form. During the initial conversation between the 
investigator/research staff and the patient, the patient m ay be asked to provide certain health 
information that is necessary to the recruitment and enrollment process. The investigator/research staff 
may also review portions of their medical records in order to further assess eligibility. They will use the 
information provided by [CONTACT_5363]/or medical record to confirm that the patient is eligible and to 
contact [CONTACT_108541]. If the patient turns out to be ineligible for the research study, the research staff will destroy all inform ation collected on the patients during the initial 
conversation and medical records review, except for any information that must be maintained for screening log purposes. Given considerable number of oral cancer cases received by [CONTACT_670338], we do not anticipate difficulty in subject recruitment.  
  
6 STUDY INTERVENTION  
 
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
Topi[INVESTIGATOR_160772] 5% cream is a TLR (Toll- like receptor) agonist. Imiquimod 5% cream is FDA approved 
for the topi[INVESTIGATOR_670311].  
• Clinically typi[INVESTIGATOR_2855], non -hyperkeratotic, non -hypertrophic actinic keratosis (AK) on the face and 
scalp in immunocompetent adults (1.1)  
• Biopsy confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; 
maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), 
only when surgical methods are medically less appropriate and patient f ollow -up can be 
reasonably assured (1.2).  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   14 • External genital and perianal warts/condyloma acuminate in patients 12 years old or older (1.3).  
Because there is no FDA approved indication for the use in the OSCC patients, we will submit 
Investigatrional New Drug (IND) application for intra- oral use of drug in OSC C patients to the FDA.  
Each gram of the 5% cream contains 50 mg of imiquimod in an off- white oil- in-water vanishing cream 
base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, purified water, benzyl alcohol, methylparaben, and propylparaben. Chemically, imiquimod is 1 -(2-methylpropyl) -1H-imidazo[4,5 -c]quinolin -4-amine. 
Imiquimod has a molecular formula of C14H16N4 and a molecular weight of 240.3.  
6.1.[ADDRESS_904941] of 28 -day cycle. Treatment will continue fo r a maximum of 28 -days or severe toxicity requiring 
cessation occurs.  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
 
6.2.1  ACQUISITION AND ACCOUNTABILITY  
 
Twenty -eight packets (single- use packets) of i miquimod Cream, 5%, will be procured by [CONTACT_941] c linical 
research pharmacy and dispensed to the patient upon request by [CONTACT_978]/study team .  The medica tion 
will either be overnighted via Fedex/UPS a day before Day 1 or delivered by [CONTACT_670339]’s home address.  Although imiquimod 5% topi[INVESTIGATOR_670312] ‘external use only’ label, it will 
be explained to the patients that it has been safely used in the vulvar, vaginal and cervical mucosa34,55, 
as well as in the oral mucosa36,54. Patients are to return all unused medication to the investigator at the 
endpoint visit, which will then be returned to the research pharmacy for proper destruction and disposal.  
 
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
Imiquimod cream (5%) are manufactured, packaged, and pre -labeled, which will be procured and 
dispensed by [CONTACT_670340].  
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904942] STORAGE AND STABILITY  
 
The study drug will be stored in the research pharmacy in room -temperature.  
  
6.2.4  PREPARATION  
 Not applicable.  
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
 
Not applicable.  
 
6.[ADDRESS_904943] compliance will be monitored with the aid of a “Patient Daily Diary” (Appendix B) which will be 
reviewed by [CONTACT_670341]. Subjects who are non -compliant with protocol schedule or 
filling out the daily diary will be removed from the study at the discretion of the study investigator.  
 
6.5 CONCOMITANT THERAPY  
 
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinician. M edications to be reported in the Case Report Form ( CRF) are 
concomitant prescription medications, over -the-counter medications and supplements . 
 
 
6.5.[ADDRESS_904944] of concomitantly administered topi[INVESTIGATOR_2855]/systemic 
corticosteroids, the case report form must capture the concurrent use of all other drugs, over- the-
counter medications, or alternative therapi[INVESTIGATOR_014].  The Principal Investigator [INVESTIGATOR_670313]. The topi[INVESTIGATOR_670314] -medicating moisturizing 
gel and oral antihistamines for itching.  

Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904945] be 
recorded.  
   
    
 
7 STUDY INTERVENTION  DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
 
Discontinuation from topi[INVESTIGATOR_160772] 5% cream  does not mean discontinuation from the study, and 
remaining study procedures should be completed as indicated by [CONTACT_4690].   If a clinically 
significant finding is identified ( including, but not limited to changes from baseline) after enrollment, the 
investigator or qualified designee will determine if any change in participant management is needed. Any new clinically relevant finding will be reported as an adverse event (AE). Patients who discontinue 
early (missing 14 or more days of daily treatment regimen) should return within [ADDRESS_904946] may be performed at that time.  
 The data to be collected at the time of study intervention discontinuation will include the following:  
• Reason for study treatment discontinuation  
• Protocol specified endpoint assessment (clinical size of lesion, concomitant medication, daily 
diary form  
• AE follow -up information : follow -up until resolution or determined by [CONTACT_670342]  
• Survival data. 
  
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
 
Participant s are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue  or withdraw a participa nt from  the study for the following reasons : 
 
• Pregnancy  
• Significant study intervention non -compliance  
• If any clinical adverse event (AE)  or other medical condition or situation occurs such that 
continued participation in the study would not be in the best interest of the participant  
• Disease progression which requires discontinuation of the study intervention  
• If the participant  meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   17 The reason for participant discontinuation  or withdrawal from the study will be recorded on the Case 
Report Form ( CRF). Subjects who sign the informed consent form and are enrolled in the study  but do 
not receive the study intervention may be replaced.  Subjects who sign the informed consent form, and 
receive the study intervention , and subsequently withdraw, or are withdrawn or discontinued  from the 
study, will be replaced.  
 
7.[ADDRESS_904947] be taken if a participant fails to return to the clinic for a required study visit:  
• The site will  attempt to contact [CONTACT_19423] 5 business days  
and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain if the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_616728]’s medical record or study file.  
• Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason o f lost to follow -up. 
  
8 STUDY ASSESSMENTS AND PROCEDURES  
  
8.1 EFFICACY ASSESSMENTS  
  
Clinical size of tumor: For the purposes of this study, patients will be evaluated for response on Day 1, 
Day [ADDRESS_904948] diameters  will be reported for each patient . 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All baseline 
evaluations should be performed as closely as possible to the beginning of treatment and never more than 5 days before the beginning of the treatment.  
Histologic response : Pre- and post -treatment tumor  tissue samples will be obtained from all [ADDRESS_904949] -treatment tissue samples will be obtained from the surgical resection tissue.  
Timing of Biopsy Samples:  The formalin -fixed, paraffin -embedded tissue samples will be obtained from 
the MUSC Oral Pathology &  Pathology Department archive d at the following time -points:  
• Prior to treatment (anytime during the screening period) (mandatory)  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   18 • Post -treatment (immediately following the surgical resection) (mandatory)  
Collection & Processing Instructions:  Collection and processing of the tissue samples will be a part of 
standard of care. For the study, representative H&E slides of the biopsy and surgical specimen will be 
examined for correlation with clinical change in tumor size.  The HCC Pathology Core laboratory will be 
notified by [CONTACT_6968] ( yoona @musc .edu) for retrieval of FFPE tissue blocks and generation of H&E slides and 
immunoblank slides. The email will contain the following information:  
• Subject ID number  
• Time point (e.g.  baseline vs end of treatment)  
 
The formalin -fixed, paraffin -embedded slides will first be stained with H&E for review and the 
representative tumor section slides will be  selected by [CONTACT_518567] -certified pathologist  (PI). The most 
representative area of the selected slides (one for biopsy and one for surgical tissue) will be  
macrodissected for further multispectral imaging (quantitative immunofluorescence). The slides w ill be  
stained with pan -cytokeratin using Lunaphore  Comet automated stainers, and the pan -cytokeratin 
positive tumor cells  for quantification of tumor cells present.  
 
In addition, the percent change in the tumor cell proliferation marker (PCNA) and immune suppression marker on tumor cells (PD -L1) will be assessed using quantitative immunofluorescence . 
  
Immunologic response :  Immunoblank s will be delivered to HIMC in person for quantitative multiplex 
immunofluorescence study. The HIMC will also be notified by [CONTACT_670343].  The email will contain the following information:  
•  Subject ID  
•  Time point (e.g. baseline vs end of treatment)  
•  Contents of samples (number of immunoblank slides for each case)  
 
The result will be reported as % change in the immune cell profiles.  
 
 
8.[ADDRESS_904950] dose of imiquimod. Subjects will be 
instructed to report all AEs during the study and will be assessed for the occurrence of AEs throughout 
the study. All AEs (serious and non -serious) must be recorded on the source documents and eCRFs 
regardless of the assumption of a causal relationship with the study drug. All AEs of unknown etiology 
associated with imiquimod exposure should be evaluated to determine if it is possibly an irAE . Therapy -
related AEs and the grade will be reported using the CTCAE v.5.0.To assess potential systemic AEs, Blood test to assess complete blood count (CBC) will be conducted prior to Day 1, and compared to th at of the 
endpoint. The endpoint blood test result will be obtained from the patient’s medical chart , which is 
performed as part of SOC prior to surgery.   
 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
  
8.3.1  DEFINITION OF ADVERSE EVENTS (AE)  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904951] medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention -related (21 CFR 312.32 (a)).  
 
 
8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
An adverse event (AE ) or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes: d eath, a life -threatening adverse 
event, inpatient hospi[INVESTIGATOR_1081], a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth d efect. Important medical events that may not result in death, be life -threatening, or 
require hospi[INVESTIGATOR_708], based upon appropriate medical judgment, they may jeopardize the participant  and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or con vulsions that do 
not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
 
 
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
 
[IP_ADDRESS]  SEVERITY OF EVENT  
 
For adverse events (AE s) not included in the protocol defined grading system, the following guidelines 
will be used to describe severi ty.  
 
• Mild  – Events require minimal or no treatment and do not interfere with the participant ’s daily 
activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe  – Events interrupt a participant ’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.   Of note, the term  “severe” does not necessarily equate to “serious”.  
 
[IP_ADDRESS]  RELATIONSHIP TO STUDY INTERVENTION  
 All adverse events ( AEs) must have their relationship to study intervention assessed by [CONTACT_237357]/her clinical judgment. 
The degree of certainty about causality will be graded using the categories below. In a clinical trial, the study product must always be suspect.  
 
• Related  – The AE is known to occur with the study intervention , there is a reasonable possibility 
that the study intervention  caused the AE , or there is a temporal relationship between the study 
intervention  and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention  and the AE. 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   20 • Not Related  – There is not a reasonable possibility that the administration of the study 
intervention  caused the event, there is no temporal relationship between the study intervention  
and event onset, or an alternate etiology has been established.  
 
 
[IP_ADDRESS]  EXPECTEDNESS  
 
The PI [INVESTIGATOR_670315] ( AE) is 
expected or unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of 
the event is not consistent with the risk information previously described for the study intervention . 
 
8.3.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP 
 The occurrence of an adverse event (AE ) or serious adverse event (SAE ) may come to the attention of 
study personnel during study visits and interviews of a study participant  presenting for medical care, or 
upon review by a study monitor.  
 All AEs including local and systemic reactions not meeting the criteria for SAE s will be captured on the 
appropriate  case report form  (CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization of the event. All AEs 
occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 Any medical condition that is present at the time that the participant  is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition  deteriorates at any 
time during the study, it will be recorded as an AE.  
 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity  to be performed. A Es characterized as intermittent require documentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
 The study team  will record all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study 
participation.  At each study visit, the investigator will inquire abou t the occurrence of AE/SAEs since the 
last visit.  Events will be followed for outcome information until resolution or stabilization.  
 
 
8.3.[ADDRESS_904952] seek information on adverse events by [CONTACT_28812], as appropriate, by [CONTACT_5148].  Information on all adverse events should be recorded 
immediately in the source document, and also in th e appropriate adverse event module of the case 
report form (CRF).  All clearly related signs, symptoms, and abnormal diagnostic procedures results 
should recorded in the source document, though should be grouped under one diagnosis.  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904953] include an assessment of whether there is a reasonable possibility that the study intervention  
caused the event. Study endpoints that are serious adverse events (e.g., all -cause mortality) must be 
reported in accordance with the protocol unless there is evidence suggesting a causal relationship between the study intervention  and the event (e.g., death from anaphylaxis). In that case, the 
investigator must immediately report the event to the sponsor . 
 
All serious adverse events ( SAEs ) will be followed until satisfactory resolution or until the site 
investigator deems the event to be chronic or the participant is stable. Other supporting documentation 
of the event may be requested by [CONTACT_36909] ( DCC)/study sponsor and should be 
provided as soon as possible.  
 The study sponsor will be responsible for notifying the Food and Drug Administration ( FDA) of any 
unexpected fatal or life -threatening suspected adverse reaction as soon as possible, but in no case later 
than 7 calendar days after the sponsor's initial receipt of the information.   In addition, the sponsor must 
notify FDA and all participating investigators in an Investigational New Drug ( IND) safety report of 
potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later 
than [ADDRESS_904954]  
 Not applicable  
 
8.3.9  REPORTING OF PREGNANCY  
 Not applicable  
 
8.4 UNANTICIPATED PROBLEMS  
 
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP) 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   22  
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participant s or others to include, in general, any incident, experience, or outcome that meets all  of the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant  population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
• Suggests that the research places participant s or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
  
8.4.2   UNANTICIPATED PROBLEM REPORTING  
 The investigator will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB) and t o the Data Coordinating C enter ( DCC)/lead principal investigator ( PI). The UP report will 
include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP ;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP . 
 To satisfy the requirement for prompt reporting, UP s will be reported using the following timeline:   
 
• UPs that are serious adverse events ( SAEs) will be reported to the IRB and to the DCC/study 
sponsor within 5-days  of the investigator becoming aware of the event.  
• Any other UP  will be reported to the IRB and to the DCC/study sponsor within 5-days  of the 
investigator becoming aware of the problem.  
• All UPs should be reported to appro priate institutional officials as required by [CONTACT_17347] ’s 
written reporting procedures , the supporting agency head (or designee), and the Office for 
Human Research Protections ( OHRP ) within 5-days  of the IRB’s receipt of the report of th e 
problem from the investig ator.  
 
 
8.4.3  REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS  
 Not applicable  
 
9 STATISTICAL CONSIDERATIONS  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   23  
 
9.1 STATISTICAL HYPOTHESES  
 
 
• Primary Efficacy Endpoint : Imiquimod 5% topi[INVESTIGATOR_670307] 28-days  will 
decrease the clinical tumor size at least by 50% with confirmation by [CONTACT_670344] . Minimal 
local and systemic adverse events are anticipated.  
 
• Secondary Efficacy Endpoint : Imiquimod will increase apoptosis and necrosis of the tumor cells 
and activate anti- tumoral immune cells. 
 
9.2 SAMPLE SIZE  DETERMINATION  
 
In the only study available, which has one patient with recurrent oral squamous cell carcinoma (OSCC), 
imiquimod achieved a complete (100%) response with 14 days of daily treatment43. To be conservative, 
we will estimate the response rate (reduction in tumor size) to be at least 0.5 with 28 days of daily imiquimod treatment. In this proof -of-concept clinical trial, we can accrue and evaluate 15 subjects 
during the allotted 2 -year stud y period. With 15 subjects and the estimate response rate of 0.5, we will 
achieve the 95% confidence interval (CI) of 0.[ADDRESS_904955] 95% CI 
based on binomial distribution. Descriptive statistics will be used to quantify secondary end points of 
toxicity and tolerability. Statistical analyses will also be conducted using SAS version 9.4 (SAS Institute Inc, Cary, NC) and R (www.r-project.org), and p<0.05 (two sided) will be considered as statistically significant. 
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904956] diameters  will be reported for each patient. 
The pan -cytokeratin positive tumor cells will be quantified and the p ercent chan ge will be calculated.  
The concordance between the p ercent change in clinical size and the tumor count will be assessed  using 
Cohen κ. 
All of the patients who meet the eligibility criteria (with the possible exception of those who received no 
study medication) will be included in the main analysis of the response rate. Patients in response 
categories [ADDRESS_904957] a treat ment failure (disease progression). Precise definitions 
for categories 4 -9 will be protocol specific.  
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT  / SAFETY ENDPOINT  
 
Descriptive statistics will be used to quantify the secondary endpoints of toxicity and tolerability.  
Summary of t herapy -related adverse events and the grade will be reported using the CTCAE v.5.0.  
 
 
9.4.[ADDRESS_904958] been identified (e.g., early death due to other reasons, early discontinuation of treatment, major protocol violations, etc.). However, these subanalyses may not serve as the ba sis for drawing conclusions concerning treatment 
efficacy, and the reasons for excluding patients from the analysis should be clearly reported. The 95% confidence intervals will also be provided.  
 
9.4.7  TABULATION OF INDIVIDUAL PARTICIPANT DATA 
 Individual participant  data will be summarized and presented as the baseline characteristics .  
  
9.4.8  EXPLORATORY ANALYSES  
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   25 The precent change in immune profile  following the imiquimod treatment (endpoint; surgical tissue) for 
each of 15 subjects will be compared to that of the baseline (biopsy tissue).  
 
Paired t -test will be performed to assess the significance of the change in the marker expression levels . 
Statistical analyses will be conducted using SAS 9.4 (SAS Institute Inc.) and p<0.05 will be considered statistically significant.  
  In addition, the percent change in the tumor cell proliferation marker (PCNA) and immune suppression 
marker on tumor cells (PD -L1) will be assessed using quantitative immunofluorescence.  
 
 
9.4.9  SURVIVAL ANALYSES  
 Using the time of data cutoff as Sep 30, 2023, the time from surgery (initial treatment) to the time to cancer recurrence (relapse -free survival) and death will be assessed.  
 The data will be shown as the  
1. mean follow -up time in months   
2. one year recurrence -free survival rate.   
 
For the recurrence -free survival rate,
 the t ime-to-event efficacy will be  estimated using two -sided 
corresponding 95% CIs.    
 
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
 
10.1 REGULATORY, ETHICAL , AND S TUDY OVERSIGHT CONSIDERATIONS  
 
 
10.1.1 INFORMED CONSENT PROCESS  
  
[IP_ADDRESS]  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS 
 Consent forms describing in detail the study intervention , study procedures, and risks are given to the 
participant  and written documentation of informed consent is required prior to starting 
intervention/administering study intervention.   The following consent materials a re submitted with this 
protocol: ECOG performance status criteria, Daily diary form.  
  
[IP_ADDRESS]  CONSENT PROCEDURES AND DOCUMENTATION  
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   26 Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation.  Consent forms will be Institutional 
Review Board ( IRB)-approved and the participant  will be asked to read and review the document. T he 
investigator will explain the research study to the participant  and answer any questions that may arise. 
A verbal explanation will be provided in terms suited to the  participant’s comprehension of the 
purposes, procedures, and potential risks of the study and of their rights as research participants.  Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participant s should have the opportunity to discuss the study with their family or  
surrogates or think about it prior to agreeing to participate. The participant  will sign the informed 
consent document prior to any procedures being done specifically for the study.  Participant s must be 
informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice.  A copy of the informed consent document will be given to the participant s for their records. 
The informed consent process will be conducted and  documented in the source document (including the 
date), and the form signed, before the participan t undergoes any study -specific procedures. The rights 
and welfare of the participant s will be protected by [CONTACT_21223].  
  
10.1.2 STUDY DISCONTINUATION AND CLOSURE  
 This study may be temporarily suspended  or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by [CONTACT_670345], the Investigational New Drug ( IND) 
and regulatory authorities .  If the study is prematurely terminated or suspended, the  Principal 
Investigator ( PI) will promptly inform study participants, the In stituti onal Review Board ( IRB), and 
sponsor and will provide the reason(s) for the termina tion or suspension.  Study participants will be 
contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that  the primary endpoint has been met  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the sponsor, IRB and/or Food and Drug Administration ( FDA). 
  
10.1.[ADDRESS_904959] by [CONTACT_3486],  their 
staff, and the sponsor  and their intervention s. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904960] ( IRB), regulatory agencies  or pharmaceutical company supplying study product may 
inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participant s in this 
study. The clinical study site will permit access to such records.  
 The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor requirements . 
 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the HCC CTO  Data Coordinating Center. This will not include the 
participant’s contact [CONTACT_1290]. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_670346]. At the end of the study, all study databases will be de -identified and archived 
at the HCC CTO  Data Coordinating Center. 
 
 
10.1.4 FUTURE USE OF STORED SPECIMENS AND DATA  
 
Data collected for this study will be analyzed and stored at the HCC  Data Coordinating Center . After the 
study is completed, the de -identified, archived data will be transmitted to and stored at the HCC  Data 
Repository , for use by [CONTACT_21227]. Permission to transmit 
data to the HCC  Data Repository  will be included in the informed consent.  
 
With the participant’s approval and as approved by [CONTACT_141238] ( IRBs ), de-
identified biological samples will be stored at the HCC  Biosample Repository  with the same goal as the 
sharing of data with the HCC  Data Repository . These samples could be used to research the causes of 
oral cancer, its complications and other conditions for which individuals with oral cancer are at 
increased risk, and to improve treatment. The HCC  will also be provided with a code -link that will allow 
linking the biological specimens with the phenotypic data from each participant, maintaining the blind ing of the identity of the participant.  
 During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to biosample storage may  not be possible after the study is completed.  
 When the study is  completed , access to study data and/or samples will be provided through the HCC.  
  
10.1.5 KEY ROLES  AND STUDY GOVERNANCE  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904961], BSB 344 MSC 507  Address  
[PHONE_13917]  Phone Number  
[EMAIL_12788]  Email  
 
  
10.1.[ADDRESS_904962] ( DSMB ) composed of 
individuals with the appropriate expertise  in oncology, research pharmacy, research nursing, and data 
management . Members of the DSMB should be independent from the study conduct and free of conflict 
of interest, or measures should be in place to minimize perceived conflict of interest.  The DSMB will 
meet at least semiannually to assess safety and efficacy data on each arm of the study. The DMSB will operate under the rules of an approved charter that will be written and reviewed at the organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to the PI N ational Institute s of Health  staff. 
 
 
10.1.[ADDRESS_904963] of 
the trial is in compliance with the currently approved protocol/amendment(s), with International Conference on Harmonisation Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s).  
 
• Monitoring for this study will be performed by [CONTACT_670347]’s DSMC .  
• On-site monitoring will be provided throughout the study with random review of certain data 
(less than 100% data verification or targeted data verification of endpoint, safet y and other key 
data variables) . 
• CTO will be provided copi[INVESTIGATOR_10376] 10 days of visit.  
• Details of clinical site monitoring are documented in a Clinical Monitoring Plan ( CMP ). The CMP 
describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports.  
• Independent audits will  be conducted by [CONTACT_670348]’s DSMC  to ensure monitoring practices are 
performed consistently across all participating sites and that monitors are following the CMP . 
 
 
10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL  
 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904964], data and biological 
specimen  collection, documentation  and completion.  An individualized quality management plan will be 
developed to descri be a site’s quality management.  
 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to the site for clarification/resolution.  
 Following written Standard Operating Procedures ( SOPs ), the monitors will verify that the clinical trial is 
conducted and data are generated  and biological specimens are collected, documented (recorded), and 
reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP ), and applicable regulatory requirements (e.g., Good Laboratory Practices ( GLP), Good 
Manufacturing Practices ( GMP )).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482].  
 
 
10.1.[ADDRESS_904965]  KEEPI[INVESTIGATOR_1645]   
 
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported . 
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.    Hardc opi[INVESTIGATOR_141213].  Data record ed in the electronic case report 
form ( eCRF ) derived from source documents should be consistent with the data recorded on the source 
documents .  
 Clinical data (including a dverse events ( AEs), concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into RedCap , a [ADDRESS_904966] protection and internal quality checks, 
such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
 
 
[IP_ADDRESS]  STUDY RECORDS RETENTION  
 [Study documents should be retained for a minimum of [ADDRESS_904967] approval of a marketing 
application in an  International Conference on Harminosation ( ICH) region and until there are no pending 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904968] elapsed since the 
formal discontinuation of clinical development of the study intervention . These documents should be 
retained for a longer period, however, if required by [CONTACT_427]. No records will be destroyed 
without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform 
the investigator when these documents no longer need to be retained.  
 
 
10.1.10  PROTOCOL DEVIATIONS  
 A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP) requirements. The 
noncompliance may be either on the part of the participant , the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 These practices are consistent with ICH GCP :  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_904969] (IRB)  per their policies . The site investigator  is responsible for knowing and 
adhering to the reviewing IRB requirements. Further details about the handling of protocol deviation s 
will be included in the MOP.  
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 This study will  be conducted in accordance with the following  publication and data sharing policies and 
regulations:  
 
National Institutes of Health ( NIH) Public Access Policy , which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central  upon acceptance for 
publication.  
 This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the  Clinical Trials Registration and Results Information Submission rule . As 
such,  this trial will be  registered at ClinicalTrials.gov , and results information  from this  trial will be 
submitted to ClinicalTrials.gov.  In addition, every attempt will be made to publish results in peer -
reviewed journals.  Data from this study may be request ed from other researchers x years after the 
completion of the primary endpoint by [CONTACT_13172] <specify person or awardee institution, or name [CONTACT_496251] >.  
 In addition, t his study will comply with the NIH Genomic Data Sharing Policy , which  applies to all NIH-
funded research that generates large -scale human or non -human genomic data, as well as the use of these 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   31 data for subsequent research. Large -scale data include genome -wide association studies (GWAS), single 
nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epi[INVESTIGATOR_141214], and gene 
expression data . 
 
10.1.[ADDRESS_904970].  
 
 
10.2 ADDITIONAL CONSIDERATIONS  
 
No additional considerations. 
 
  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904971]  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
LSMEANS  Least -squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
MUSC  Medical University of South Carolina  
NCT National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
OSCC  Oral Squamous Cell Carcinoma  
PI [INVESTIGATOR_670316] 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904972] Operating Procedure  
UP Unanticipated Problem  
US [LOCATION_002]  
 
  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   34 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
Version  Date  Description of Change  Brief Rationale  
8 1/21/2022  Change of Institution   
9 8/30/2023  Addition of tumor cell count 
quantification using 
immunofluorescence in the primary 
endpoint assessment  
 
Additional statistical analyses   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   35     
 
  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   36 11 REFERENCES  
 
1. Sasahira T, Kirita T. Hallmarks of cancer- related newly prognostic factors of oral squamous cell 
carcinoma. Int J Mol Sci 2018;19:2413.  
2. Kademani D. Oral cancer. Mayo Clin Proc 2007;82:878 -887.  
3. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epi[INVESTIGATOR_670317] -
positive head and neck squamous cell carcinoma. J Clin Oncol 2015;33:3235 -3242.  
4. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195 -215.  
5. Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J 2012;6:126 -
130.  
6. Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral 
squamous cell carcinoma. Int J Clin Oncol 2014;19:423 -430.  
7. Cramer JD, Reddy A, Ferris RL, Duvvuri U, Samant S. Comparison of the seventh and eighth edition American Joint Committee on cancer oral cavity staging systems. Laryngoscope 
2018;128:2351 -2360.  
8. Huang SH, O’Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. 
Curr Treat Options in Oncol 2017;18:40. 
9. Lydiatt WM, Patel SG, O’Sullivan B, et al. Head and neck cancers -major changes in the American 
Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:122 -
137.  
10. Moeckelmann N, Ebrahimi A, Tou YK, et al. Prognostic implications of the 8th edition American Joint Committee on Cancer (AJCC) staging system in oral cavity squamous cell carcinoma. Oral Oncol 2018;85:82- 86. 
11. Tirelli G, Gatto A, Nata FB, et al. Prognosis of oral cancer: a comparison of the staging systems 
given in the 7th and 8th editions of the American Joint Committee on cancer staging manual. Br 
J Oral Maxillofac Surg 2018;56:8 -13. 
12. Faisal M, Bakar MA, Sarwar A, et al. Depth of invasion (DOI) as a predictor of cervical nodal metastasis and local recurrence in early stage squamous cell carcinoma of oral tongue (ESSCOT). PLoS ONE 2018;13:e0202632.  
13. Almangush A, Makitie AA, Makinen LK, et al. Small oral tongue cancers (<4cm in diameter) with clinically negative neck: from the 7th to the 8th edition of the American Joint Committee on cancer. Virchows Archiv 2018;473:481 -487.  
14. Baykul T, Yilmaz HH, Aydin U, Aydin MA, Aksoy MC, Yildirim D. Early diagnosis of oral cancer. J Int Med Res 2010;38:737- 749.  
15. Yoon AJ, Wang S, Wang T, Kutler DI, La[COMPANY_002] D, Philipone E, Peters SM, Hernandez B, McDowell BD, Stewart CR, Momen -Heravi F, Santella RM. MicroRNA -based risk scoring system to identify 
early -stage oral squamous cell carcinoma patients at high -risk for cancer- specific mortality. Head 
Neck 2020. doi.org/10.1002/hed.[ZIP_CODE].  
16. Amaravadi RK, Thompson CB. The roles of therapy -induced autophagy and necrosis in cancer 
treatment. Clin Cancer Res 2007;13:7271 -7279.  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   37 17. Katayama M, Kawaguchi T, Berger MS, Pi[INVESTIGATOR_51706]. DNA damaging agent- induced autophagy 
produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death 
Differ 2007;14:548– 558.  
18. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death 
in breast cancer cells following DNA damage. Cell Death Differ 2007;14:500 –510.  
19. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53 -induced modulator of autophagy, is critical 
for apoptosis. Cell 2006;126:121 –134.  
20. Rose TL, Bonneau L, Der C, Marty -Mazars D, Marty F. Starvation -induced expression of 
autophagy -related genes in Arabidopsis. Biol Cell 2006;98:53 –67. 
21. Ahn MY, Kwon SM, Cheong HH, Park JH, Lee J, Min SK, Ahn SG, Yoon JH. Toll -like receptor [ADDRESS_904973], Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J 
Oral Pathol Med 2012;41:540- 546.  
22. Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, 
Wolchok JD, Schwartz GK, Carvajal RD. Treatment of locally recurrent mucosal melanoma with 
topi[INVESTIGATOR_160772]. J Clin Oncol 2011;29:e809 -e811.  
23. Schon MP, Schon M. Imiquimod: mode of action. British J Dermatol 2007;157:8 -13. 
24. Sohn KC, Li ZJ, Choi DK, Zhang T, Lim JW, Chang IK, Hur GM, Im M, Lee Y, Seo YJ, Lee JH, Kim CD. 
Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20. 2014;9:e95337.  
25. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571 -577.  
26. Geisse JK, Rich P, Pandya A, Gross K, Andres K, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double -blind, randomized, vehicle -controlled study. J Am Acad 
Dermatol 2002;47:390- 398.  
27. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, et al. Tumoricidal activity of TLR7/8 -activated 
inflammatory dendritic cells. J Exp Med 2007;204:1441 -1451.  
28. Bong AB, Bonnekoh B, Franke I, Schön M, Ulrich J, et al. Imiquimod, a topi[INVESTIGATOR_670318], in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135- 138.  
29. Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, et al. Imiquimod enhances IFN -gamma 
production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 2009;129:2676 -2685.  
30. Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Digiovanni J, et al. Imiquimod attenuates the growth of UVB- Induced SCC in mice through Th1/Th17 cells. Mol Carcinog 2013;52:760 -769.  
31. Rich AM, Hussaini HM, Parachuru V, Seymour GJ. Toll- like receptors and cancer, particularly oral 
squamous cell carcinoma. Front Immunol 2014;5:464.  
32. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle -controlled phase III study in Europe. Br J 
Dermatol 2005;152:939- 947.  
33. Love WE, Bernhard JD, Bordeaux JS. Topi[INVESTIGATOR_670319]: A systematic review. Arch Dermatol 2009;145:1431 -1438.  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   38 34. Iavazzo C, Pi[INVESTIGATOR_670320] E, Athanasiou S, et al. Imiquimod for treatment of vulvar and vaginal 
intraepi[INVESTIGATOR_28601]. Int J Gynaecol Obstet 2008;101:3 -10. 
35. Gkoulioni V, Eleftheriadou A, Yiotakis I, Ferekidou E, Chrisovergis A, Lazaris AC, et al. The efficacy 
of imiquimod on dysplastic lesions of the oral mucosa: an experimental model. Anticancer Res 
2010;30:2891- 2896.  
36. Wester A, Eyler JT, Swan JW. Topi[INVESTIGATOR_670321]. JAAD Case Reports 2017;3:329 -331.  
37. Schmitz A, Duhoux F, Machiels JP. Window of opportunity studies: Do they fulfil our 
expectations? Cancer Treat Rev 2016;43:50 -57. 
38. Marous M, Bieche I, Paoletti X, Alt M, Razak AR, Stathis A. et al. Designs of preoperative biomarkers trials in oncology: a systemic review of the literature. Ann Oncol 2015;26:2419 -2428.  
39. Torezan LA, Festa -Neto C. Cutaneous field cancerization: clinical, histopathological and 
therapeutic aspects. An Bras Dermatol 2013;88:775 -786.  
40. Christensen SR. Recent advances in field cancerization and management of multiple cutaneous 
squamous cell carcinomas. 2018;7: doi: 10.[ZIP_CODE]/f1000research.[ZIP_CODE].1.  
41. Wang B, Zhang S, Yue K, Wang XD. The recurrence and survival of oral squamous cell carcinoma: 
a report of 275 cases. Chin J Cancer 2013;32:614 -618.  
42. Gombos K, Horvath R, Szele E, et al. miRNA expression profiles of oral squamous cell carcinomas. Anticancer Res 2013;33:1511 -1517.  
43. Troiano G, Mastrangelo F, Caponio VCA, et al. Predictive prognostic value of tissue -based 
microRNA expression in oral squamous cell carcinoma: a systemic review and meta- analysis. J 
Dent Res 2018;97:759- 766.  
44. Sarode GS, Sarode SC, Maniyar N, Anand R, Patil S. Oral cancer database: a comprehensive review. J Oral Pathol Med 2018;47:547 -556.  
45. Kumarasamy C, Madjav MR, Sabarimurugan S, et al. Prognostic value of miRNAs in head and neck cancers: a comprehensive systemic and meta- analysis. Cells 2019;8. doi: 
10.3390/cells8080772.  
46. Megill C, Wilkin T. Topi[INVESTIGATOR_670322] -grade squamous 
intraepi[INVESTIGATOR_12184]. Semin colon Rectal Surg. 2017;28:[ADDRESS_904974], Kitchener HC. Phase II trial of 
imiquimod and HPV therapeutic vaccination in patients with vulvar intraepi[INVESTIGATOR_28601]. Br J 
Cancer 2010;102:1129 -1136.  
48. Tristram A, Hurt CN, Madden T, et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepi[INVESTIGATOR_28601] (RT
3VIN): a multicenter, open -label, randomized, 
phase 2 trial. Lancet Oncol 2014;15:1361- 1368.  
49. Singal A, Daulatabad D, Pandhi D, Arora VK. Facial basal cell carcinoma treated with topi[INVESTIGATOR_2855] 5% imiquimod cream with dermoscopic evaluation. J Cutan Aesthet Surg 2016;9:122 -125.  
50. Geisse J, Caro I, Lindholm J, Golitz  L, Stampone P, Owens M. Imiquimod 5% cream for the 
treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle -
controlled studies. J Am Acad Dermatol 2004;50:722 -33. 
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_904975], Wu A, Blake Z, Lu Y, Askin KN, et al. Quantitative 
analysis of immune infiltrates in primary melanoma. Cancer Immunol Res 2018;6:481 -493.  
52. Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA, et al. Validation of multiplex 
immunofluorescence panels using multispectral microscopy for immune -profiling of formalin -
fixed and paraffin -embedded human tumor tissues. Sci Rep 2017;17:[ZIP_CODE].  
53.  Koyama T, Chen H. “Proper Inference from Simon’s Two -Stage Designs.” Statistics in Medicine 
2008;27(16), 3145 –3154.  
54. Mane S, Patilsoman B, Bhate P, Das D, Malusare P, Tomar N. To evaluate the efficacy and 
tolerability of topi[INVESTIGATOR_2855] 5% imiquimod in cases of oral leukoplakia: a pi[INVESTIGATOR_799]. J Indian Acad Oral 
Med Rad 2021;33:27 -31. https://www.jiaomr.in/text.asp?2021/33/1/27/[ADDRESS_904976], Barton DL, Clayton AH, et al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol 2012;206:e1 -42. doi: 
10.1016/j.ajog.2011.06.105  
 
  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   40 APPENDIX A: ECOG PERFORMANCE STATUS CRITERIA.  
 
 
Grade  Descriptions  
0 Normal activity.  Fully active, able to carry on all pre -disease performance without 
restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but unable to 
carry out any work activities.  Up and about more than 50% of waking hours.  
3 In bed >50% of the time.  Capable of only limited self -care, confined to bed or 
chair more than 50% of waking hours.  
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  Totally 
confined to bed or chair.  
5 Dead.  
 
  
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   41 APPENDIX B: DAILY DIARY  
 
Exploratory clinical trial of topi[INVESTIGATOR_241129] 5% cream as window -of-opportunity monotherapy for 
early -stage oral cancer  
 
Patient Name: _____________________ Study ID: ______________ MRN:_________________  
(To be Completed by [INVESTIGATOR_41886])  
Total Daily Dose of Imiquimod: 5mg  
 
PLEASE FILL OUT AND BRING THIS SHEET AT YOUR NEXT VISIT.  
SPECIAL INSTRUCTIONS 
 1. Imiquimod 5% cream should be applied once a day at bedtime.  
2. Missed doses should be skipped and not taken as a double dose at the next dosing time.  
 3. Imiquimod 5% cream should be stored at room temperature . 
    
Day Medication  Date  Time  Comments  
Example  Imiquimod  5/1/2021  9:00PM   
1 Imiquimod     
2 Imiquimod     
3 Imiquimod     
4 Imiquimod     
5 Imiquimod     
6 Imiquimod     
7 Imiquimod     
8 Imiquimod     
9 Imiquimod     
10 Imiquimod     
11 Imiquimod     
12 Imiquimod     
13 Imiquimod     
14 Imiquimod     
15 Imiquimod     
16 Imiquimod     
17 Imiquimod     
18 Imiquimod     
Neoadjuvant Imiquimod for Oral Cancer  Version 9.3 
Protocol # 103625 15 NOV 2023 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   42 19 Imiquimod     
20 Imiquimod     
21 Imiquimod     
22 Imiquimod     
23 Imiquimod     
24 Imiquimod     
25 Imiquimod     
26 Imiquimod     
27 Imiquimod     
28 Imiquimod     
 
 
Patient Signature: ___________________________________________ Date: _____________  
Consenting Professional/Research RN Signature: ____________________ Date: ______________  
Consenting Professional/Research RN Comments: 
_________________________________________________________________________________  
_________________________________________________________________________________  
_________________________________________________________________________________  
 
 